In a study, blocking the immune system complement protein C3 was shown to reduce MS disease severity in older mice but not in ...

The investigational therapy fenebrutinib was as effective as Ocrevus for reducing disability progression in people with PPMS, a trial showed.

Researchers developed a mouse model of multiple sclerosis that captures the features of progression independent of relapse ...

After up to three years on GA Depot, most people with PPMS have not experienced any disability progression, according to new ...

Teva Canada and Novartis Canada are collaborating to ensure continued access to Mayzent for people with active SPMS in Canada ...

A small study suggests Mavenclad’s effectiveness in MS may be linked to how regulatory T-cells respond to treatment.

Scientists at the 2026 ACTRIMS forum meet to assess current approaches and explore new directions for MS research and care.

BTK inhibitors such as tolebrutinib or evobrutinib work about as well as Aubagio at preventing relapses in MS, a review of ...

Researchers have found that new myelin-making cells are constantly being made in the brain and spinal cord, even in the ...

A higher adherence to a Mediterranean diet is linked to a lower risk of developing MS, particularly in nonsmokers and people ...

A brief, four-session stress management program helped ease symptoms of depression and anxiety and reduced stress in people ...

Difficulty walking with MS is not just about physical limitations, but also emotions, stigma, and how others respond, a ...